Target intelligence / Profile preview

Terminal uridylyltransferase 7 (TUT7)

Target
TUT7
Molecular classification
Enzyme, Non-canonical terminal nucleotidyltransferase, RNA-modifying enzyme
01

Overview

Terminal uridylyltransferase 7 (TUT7) is a cytoplasmic enzyme encoded by the ZCCHC6 gene in humans. It belongs to the family of non-canonical terminal nucleotidyltransferases and catalyzes the template-independent addition of uridine residues to the 3' end of RNA substrates, specifically targeting mRNAs with short poly(A) tails and certain precursor microRNAs (pre-miRNAs). TUT7 plays a central role in regulating the stability and maturation of mRNA and miRNA molecules by: - Promoting mRNA degradation via 3′ uridylation, targeting transcripts with short poly(A) tails for decay[1]. - Mediating the biogenesis of let-7 and other microRNAs; for group II pre-miRNAs with a 1-nt 3′ overhang, TUT7 monouridylates to facilitate Dicer processing and maturation; for aberrant or trimmed pre-miRNAs, TUT7 adds oligo(U) tails, marking them for degradation[3][4][5]. - Participating in innate immune responses by modulating mRNA stability of inflammatory mediators downstream of TLR4 signaling[2]. TUT7 acts redundantly or synergistically with TUT4, especially in miRNA biogenesis, and can be implicated in diseases involving alteration in RNA metabolism, inflammation, or miRNA-regulated gene networks[5].

Other names
Zinc finger CCHC domain-containing protein 6ZCCHC6TUTase 7PAP associated domain containing 6PAPD6TENT3BHS2KIAA1711FLJ13409
02

Biological functions

mRNA degradationmicroRNA (miRNA) biogenesisRegulation of RNA stabilityPre-microRNA maturationInnate immune response modulationCellular gene expression regulation
03

Disease associations

InflammationOsteoarthritisPossible roles in cancer and infection (emerging evidence from miRNA pathway involvement)
04

Safety considerations

No well-established safety concerns or therapeutic challenges; as an RNA modification enzyme, off-target transcriptome effects could be a theoretical risk in any future therapeutics

Beyond the preview

Go deeper on Terminal uridylyltransferase 7 (TUT7).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Terminal uridylyltransferase 7 (TUT7).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call